Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCNNASDAQ:ELYMNASDAQ:SCLXNASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$2.95+6.5%$2.90$1.27▼$9.47$9.47M1.671.29 million shs33,766 shsELYMEliem Therapeutics$1.22-2.4%$1.24$2.35▼$11.55$36.30M-0.39486,688 shs114,913 shsSCLXScilex$5.13-9.2%$6.05$3.60▼$80.50$35.66M1.161,632 shs129,157 shsSCYXSCYNEXIS$0.86-3.8%$0.91$0.72▼$2.60$33.56M1.65165,651 shs130,235 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+3.51%-6.47%-14.49%+10.49%-1.01%ELYMEliem Therapeutics-2.40%+0.83%-3.94%-15.86%-84.09%SCLXScilex-9.20%+12.75%+8.23%-37.89%-87.14%SCYXSCYNEXIS-3.84%+10.82%-12.95%-16.50%-61.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCNCyclerion Therapeutics2.536 of 5 stars0.05.00.00.03.63.30.6ELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASCLXScilex2.4479 of 5 stars3.33.00.00.02.71.70.6SCYXSCYNEXIS0.5899 of 5 stars0.02.00.00.03.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion Therapeutics 0.00N/AN/AN/AELYMEliem Therapeutics 0.00N/AN/AN/ASCLXScilex 2.60Moderate Buy$455.008,769.40% UpsideSCYXSCYNEXIS 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CYCN, SCLX, ELYM, and SCYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025SCLXScilexD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/11/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/2/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$770.00 ➝ $630.002/28/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$770.00 ➝ $770.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$2.08M4.55N/AN/A$4.62 per share0.64ELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/ASCLXScilex$50.71M0.70N/AN/A($1.10) per share-4.66SCYXSCYNEXIS$2.63M12.76$1.48 per share0.58$1.96 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$5.26M-$1.16N/A∞N/AN/A-55.32%-48.35%8/5/2025 (Estimated)ELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/ASCLXScilex-$114.33M-$29.02N/AN/AN/A-159.10%N/A-93.65%8/12/2025 (Estimated)SCYXSCYNEXIS$67.04M-$0.56N/A17.20N/A-425.41%-66.21%-38.84%8/6/2025 (Estimated)Latest CYCN, SCLX, ELYM, and SCYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SCYXSCYNEXIS-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million3/12/2025Q4 2024SCYXSCYNEXIS-$0.22-$0.09+$0.13-$0.09N/A$0.98 million3/4/2025Q4 2024CYCNCyclerion TherapeuticsN/A$0.22N/A$0.22N/A$1.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A5.075.07ELYMEliem TherapeuticsN/A60.4160.41SCLXScilexN/A0.140.13SCYXSCYNEXISN/A3.133.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%ELYMEliem Therapeutics69.76%SCLXScilex69.67%SCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics34.30%ELYMEliem Therapeutics4.70%SCLXScilex7.65%SCYXSCYNEXIS4.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics303.21 million1.73 millionNo DataELYMEliem Therapeutics929.75 million28.35 millionNot OptionableSCLXScilex806.95 million222.07 millionOptionableSCYXSCYNEXIS6039.02 million36.87 millionOptionableCYCN, SCLX, ELYM, and SCYX HeadlinesRecent News About These CompaniesSCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSKMay 30 at 4:58 PM | nasdaq.comSCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA HoldMay 29 at 12:57 AM | insidermonkey.comSCYNEXIS Resumes Patient Dosing in Phase 3 MARIO StudyMay 28 at 8:30 AM | globenewswire.comSCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | finance.yahoo.comScynexis to present preclinical data on SCY-247 at ESCMID MeetingApril 9, 2025 | markets.businessinsider.comSCYNEXIS Full Year 2024 Earnings: Misses ExpectationsMarch 14, 2025 | finance.yahoo.comSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | markets.businessinsider.comSCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study RestartMarch 12, 2025 | quiverquant.comSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | globenewswire.comSCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal InfectionsDecember 18, 2024 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)December 5, 2024 | markets.businessinsider.comSCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy RatingNovember 9, 2024 | markets.businessinsider.comSCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | globenewswire.comInvestors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five yearsOctober 30, 2024 | finance.yahoo.comSCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | globenewswire.comFederated Hermes, Inc. Expands Stake in SCYNEXIS IncOctober 7, 2024 | finance.yahoo.comSCYNEXIS (NASDAQ:SCYX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024October 3, 2024 | globenewswire.comSCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Acquires 20,000 SharesSeptember 17, 2024 | insidertrades.comSCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment ConferenceAugust 27, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYCN, SCLX, ELYM, and SCYX Company DescriptionsCyclerion Therapeutics NASDAQ:CYCN$2.95 +0.18 (+6.50%) Closing price 05/30/2025 03:55 PM EasternExtended Trading$2.86 -0.09 (-2.88%) As of 05/30/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Eliem Therapeutics NASDAQ:ELYM$1.22 -0.03 (-2.40%) As of 05/29/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Scilex NASDAQ:SCLX$5.13 -0.52 (-9.20%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$5.07 -0.06 (-1.27%) As of 05/30/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.SCYNEXIS NASDAQ:SCYX$0.86 -0.03 (-3.84%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.87 +0.01 (+0.70%) As of 05/30/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
